Update your location to show providers, locations, and services closest to you.
Dr. Ilyas Sahin is an esteemed Assistant Professor of Medicine at the University of Florida, where he specializes in gastroesophageal and hepatobiliary cancers. With an MD earned with High Honors from Hacettepe University Faculty of Medicine in Ankara, Turkey, Dr. Sahin has cultivated a distinguished career in internal medicine, hematology, and oncology. His postgraduate journey led him through residencies and fellowships at internationally recognized institutions, including Harvard University and Brown University.
As a board-certified professional in Internal Medicine, Medical Oncology, and Hematology, Dr. Sahin brings a depth of expertise to his clinical and research work. He has been a pivotal figure in numerous clinical trials, focusing on innovative treatments in his areas of specialization. Beyond his clinical endeavors, Dr. Sahin is a prolific contributor to medical literature, with over 50 publications to his name, underscoring his commitment to advancing medical knowledge.
In the academic realm, Dr. Sahin holds editorial and reviewer roles in several prestigious medical journals, reflecting his broad influence and respect in the medical community. Dr. Sahin's dedication to his field is not only evident in his clinical and research accomplishments but also in his role as an educator and mentor, guiding the next generation of medical professionals at the University of Florida.
This is a multi-center, open-label, randomized, phase 2/3 trial of the bispecific antibody CTX-009 plus paclitaxel versus paclitaxel in patients with previously treated, unresectable advanced or metastatic biliary tract cancers.
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or…
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.
Please note: Some physicians and practices might not accept a specific insurance plan. Our list is also subject to change, and sometimes that change is not yet reflected in this list. Please contact the practice to confirm that your insurance is accepted. A representative will be happy to assist you.
